Incyte Corp.
INCY
Get informed when a big investor buys or sells
+ FollowEarnings Call Q4 2025
February 10, 2026 - AI Summary
Exclusive for Stockcircle Pro members
Sign up
Current Fair Value
114.3% upsideUndervalued by 114.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $19.33 Billion |
|---|---|
| Enterprise Value | $15.90 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $6.59 |
| Beta | 0.8 |
| Outstanding Shares | 199,343,000 |
Return
| Return on Equity | 25.79% |
|---|---|
| Return on Assets | 19.51% |
| Return on Invested Capital | 29.43% |
Valuation & Multiples
| P/E Ratio | 13.47 |
|---|---|
| PEG | 14.68 |
| Price to Sales | 3.77 |
| Price to Book Ratio | 3.63 |
| Enterprise Value to Revenue | 2.97 |
| Enterprise Value to EBIT | 9.24 |
| Enterprise Value to Net Income | 11 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.9710▼ 62.53% |
|---|---|
| Total Calls | 350,732▼ 2.75% |
| Total Puts | 340,566▼ 40.84% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 103.47%▲ 0.65% |
|---|---|
| Total Invested | $18.99B▼ 4.31% |
| Investors Holding | 832▼ 8.00% |
ESG Score
No data
About Incyte Corp.
CEO: Paul Friedman Relevant Senate Committees
Has primary jurisdiction over taxation, trade, and entitlement programs like Medicare and Medicaid. Decisions on drug pricing within these programs (e.g., Medicare Part D reform) and corporate tax policy directly impact Incyte's revenue, profitability, and market access. Committee members would have highly material non-public information on these critical financial drivers.
Possesses direct regulatory authority over the FDA (drug approval process), NIH (research funding), and public health initiatives. This committee's decisions directly impact Incyte's R&D, clinical trials, product approval timelines, and market access. Members would possess highly material non-public information.
Has critical oversight of intellectual property (patents), which is foundational to the biopharmaceutical business model. Also reviews antitrust matters, potentially impacting mergers and market competition within the pharmaceutical sector. Members would be privy to non-public information regarding IP litigation or antitrust investigations.